Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT2 | P31751 | 1/20 | 0.34 |
| ▸ | CLK2 | P49760 | 1/20 | 0.34 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.34 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.34 |
| ▸ | SNCA | P37840 | 1/20 | 0.33 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.32 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.32 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.32 |
| ▸ | CNR1 | P21554 | 3/20 | 0.32 |
| ▸ | CNR2 | P34972 | 3/20 | 0.32 |
| ▸ | F10 | P00742 | 2/20 | 0.32 |
| ▸ | HCAR1 | Q9BXC0 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7043479 | 0.89 | CNR1 (0.34) | AKT2CLK2DYRK1ACLK4SNCA | |
| SCHEMBL7045380 | 0.85 | SNCA (0.36) | SNCAPTGS1PTGS2CNR1CNR2 | |
| SCHEMBL3765374 | 0.84 | NR1I2 (0.38) | CNR1CNR2F10HCAR1 | |
| SCHEMBL7040511 | 0.82 | SNCA (0.38) | AKT2CLK2DYRK1ACLK4SNCA | |
| SCHEMBL7042344 | 0.82 | AMY1A (0.36) | SNCACNR1CNR2F10 | |
| SCHEMBL7042374 | 0.82 | CNR1 (0.35) | SNCACNR1CNR2F10 | |
| SCHEMBL7043221 | 0.80 | KMT2A (0.44) | SNCAPTGS1PTGS2HSP90AA1F10 | |
| SCHEMBL7043464 | 0.78 | CNR1 (0.34) | CNR1CNR2F10 | |
| SCHEMBL7045461 | 0.76 | NR1I2 (0.37) | CNR1CNR2F10 | |
| SCHEMBL7039920 | 0.75 | F10 (0.31) | CNR1CNR2F10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6613786-B2 | Treating urinary incontinence, asthma, irritable bowel syndrome or male erectile dysfunction | BRISTOL-MYERS SQUIBB COMPANY | 2003-09-02 | — | — | US | claimed |
| US-20030144333-A1 | Thiophenyl triazol-3-one derivatives as smooth muscle relaxants | HEWAWASAM PIYASENA (US) | 2003-07-31 | — | — | US | claimed |
| US-7846671-B2 | Methods of screening for agents that modulate the interaction of RGS and Gαq and urinary incontinence | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-12-07 | — | — | US | disclosed |
| US-7846671-B2 | Methods of screening for agents that modulate the interaction of RGS and Gαq and urinary incontinence | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-12-07 | — | — | US | disclosed |
| US-7846671-B2 | Methods of screening for agents that modulate the interaction of RGS and Gαq and urinary incontinence | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-12-07 | — | — | US | disclosed |
| US-20070065883-A1 | Molecules that modulate Galphaq activity and methods of treating urinary incontinence | BRISTOL-MYERS SQUIBB COMPANY | 2007-03-22 | — | — | US | disclosed |
| US-20070065883-A1 | Molecules that modulate Galphaq activity and methods of treating urinary incontinence | BRISTOL-MYERS SQUIBB COMPANY | 2007-03-22 | — | — | US | disclosed |
| US-20070065883-A1 | Molecules that modulate Galphaq activity and methods of treating urinary incontinence | BRISTOL-MYERS SQUIBB COMPANY | 2007-03-22 | — | — | US | disclosed |
| EP-1499279-A4 | MOLECULES THAT MODULATE GaQ ACTIVITY AND METHODS OF TREATING URINARY INCONTINENCE | BRISTOL MYERS SQUIBB CO (US) | 2006-07-12 | — | — | EP | disclosed |
| EP-1499279-A2 | MOLECULES THAT MODULATE GaQ ACTIVITY AND METHODS OF TREATING URINARY INCONTINENCE | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-01-26 | — | — | EP | disclosed |
| US-20040014135-A1 | Molecules that modulate Galphaq avtivity and methods of treating urinary incontinence | BRISTOL-MYERS SQUIBB COMPANY | 2004-01-22 | — | — | US | disclosed |
| US-6613786-B2 | Treating urinary incontinence, asthma, irritable bowel syndrome or male erectile dysfunction | BRISTOL-MYERS SQUIBB COMPANY | 2003-09-02 | — | — | US | disclosed |
| WO-2003063784-A2 | MOLECULES THAT MODULATE GαQ ACTIVITY AND METHODS OF TREATING URINARY INCONTINENCE | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-08-07 | — | — | WO | disclosed |
| US-20030144333-A1 | Thiophenyl triazol-3-one derivatives as smooth muscle relaxants | HEWAWASAM PIYASENA (US) | 2003-07-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030144333-A1 | Thiophenyl triazol-3-one derivatives as smooth muscle relaxants | PDE3A, ADRB2, ADRB3 | AKT2 2893/4885CLK2 923/4885DYRK1A 1537/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.